Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Covington
Citi
Healthtrust
Cipla
US Army
Argus Health
US Department of Justice
Cerilliant
UBS
Boehringer Ingelheim

Generated: October 23, 2017

DrugPatentWatch Database Preview

Daiichi Company Profile

« Back to Dashboard

What is the competitive landscape for DAIICHI, and what generic alternatives to DAIICHI drugs are available?

DAIICHI has twelve approved drugs.

There are five US patents protecting DAIICHI drugs.

There are two hundred and fifty-eight patent family members on DAIICHI drugs in thirty-six countries and fifty-five supplementary protection certificates in ten countries.

Summary for Applicant: Daiichi

International Patents:258
US Patents:5
Tradenames:10
Ingredients:10
NDAs:12
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Daiichi Sankyo Inc
MORPHABOND ER
morphine sulfate
TABLET, EXTENDED RELEASE;ORAL206544-004Oct 2, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Daiichi Sankyo Inc
SAVAYSA
edoxaban tosylate
TABLET;ORAL206316-001Jan 8, 2015RXYesNo► Subscribe► SubscribeY ► Subscribe
Daiichi Sankyo Inc
SAVAYSA
edoxaban tosylate
TABLET;ORAL206316-002Jan 8, 2015RXYesNo► Subscribe► SubscribeY ► Subscribe
Daiichi Sankyo
BENICAR HCT
hydrochlorothiazide; olmesartan medoxomil
TABLET;ORAL021532-003Jun 5, 2003ABRXYesNo► Subscribe► Subscribe ► Subscribe
Daiichi Sankyo
AZOR
amlodipine besylate; olmesartan medoxomil
TABLET;ORAL022100-002Sep 26, 2007ABRXYesNo► Subscribe► Subscribe ► Subscribe
Daiichi Sankyo Inc
MORPHABOND ER
morphine sulfate
TABLET, EXTENDED RELEASE;ORAL206544-004Oct 2, 2015RXYesYes► Subscribe► Subscribe► Subscribe
Daiichi Sankyo Inc
MORPHABOND ER
morphine sulfate
TABLET, EXTENDED RELEASE;ORAL206544-002Oct 2, 2015RXYesNo► Subscribe► Subscribe► Subscribe
Daiichi Sankyo Inc
EVOXAC
cevimeline hydrochloride
CAPSULE;ORAL020989-002Jan 11, 2000ABRXYesYes► Subscribe► Subscribe► Subscribe
Daiichi Sankyo Inc
SAVAYSA
edoxaban tosylate
TABLET;ORAL206316-001Jan 8, 2015RXYesNo► Subscribe► SubscribeY ► Subscribe
Daiichi Sankyo Inc
ROXYBOND
oxycodone hydrochloride
TABLET;ORAL209777-002Apr 20, 2017RXNoNo► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Daiichi

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Daiichi Sankyo
WELCHOL
colesevelam hydrochloride
FOR SUSPENSION;ORAL022362-001Oct 2, 2009► Subscribe► Subscribe
Daiichi Sankyo
TRIBENZOR
amlodipine besylate; hydrochlorothiazide; olmesartan medoxomil
TABLET;ORAL200175-001Jul 23, 2010► Subscribe► Subscribe
Daiichi Sankyo
WELCHOL
colesevelam hydrochloride
FOR SUSPENSION;ORAL022362-002Oct 2, 2009► Subscribe► Subscribe
Daiichi Sankyo
WELCHOL
colesevelam hydrochloride
TABLET;ORAL021176-001May 26, 2000► Subscribe► Subscribe
Daiichi Sankyo
WELCHOL
colesevelam hydrochloride
FOR SUSPENSION;ORAL022362-001Oct 2, 2009► Subscribe► Subscribe
Daiichi Sankyo
WELCHOL
colesevelam hydrochloride
FOR SUSPENSION;ORAL022362-002Oct 2, 2009► Subscribe► Subscribe
Daiichi
FLOXIN OTIC
ofloxacin
SOLUTION/DROPS;OTIC020799-001Dec 16, 1997► Subscribe► Subscribe
Daiichi Sankyo
BENICAR
olmesartan medoxomil
TABLET;ORAL021286-001Apr 25, 2002► Subscribe► Subscribe
Daiichi Sankyo
WELCHOL
colesevelam hydrochloride
FOR SUSPENSION;ORAL022362-002Oct 2, 2009► Subscribe► Subscribe
Daiichi Sankyo
WELCHOL
colesevelam hydrochloride
TABLET;ORAL021176-001May 26, 2000► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for DAIICHI drugs

Drugname Dosage Strength Tradename Submissiondate
colesevelam hydrochloride
Powder for Oral Suspension1.875 g/Packet and 3.75 g/Packet
WELCHOL
4/9/2010
colesevelam hydrochloride
Tablets625 mg
WELCHOL
7/1/2009
cevimeline hydrochloride
Capsules30 mg
EVOXAC
2/27/2009
amlodipine besylate and olmesartan medoxomil
Tablets10 mg/20 mg and 5 mg/40 mg
AZOR
3/31/2008
amlodipine besylate and olmesartan medoxomil
Tablets5 mg/20 mg and 10 mg/40 mg
AZOR
2/11/2008
olmesartan medoxomil and hydrochlorothiazide
Tablets20 mg/12.5 mg
BENICAR HCT
5/11/2007
olmesartan medoxomil and hydrochlorothiazide
Tablets40 mg/12.5 mg and 40 mg/25 mL
BENICAR HCT
2/15/2007
olmesartan medoxomil
Tablets5 mg, 20 mg and 40 mg
BENICAR
4/25/2006

Non-Orange Book Patents for Daiichi

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,646,171 Angiotensin II antagonist 1-biphenylmethylimidazole compounds and their therapeutic use► Subscribe
7,342,014Diamine derivatives► Subscribe
7,541,024Low salt forms of polyallylamine► Subscribe
9,707,296Pharmaceutical composition► Subscribe
7,261,880Methods of treating Syndrome X with aliphatic polyamines► Subscribe
8,377,428Low salt forms of polyallylamine► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Daiichi Drugs

Country Document Number Estimated Expiration
European Patent Office1392331► Subscribe
Germany69231801► Subscribe
Hong Kong1095814► Subscribe
China1189490► Subscribe
Japan2004535384► Subscribe
JapanH07121918► Subscribe
Japan4499363► Subscribe
Czech Republic289244► Subscribe
Australia661153► Subscribe
Portugal573218► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Daiichi Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00499Netherlands► SubscribePRODUCT NAME: COMBINATIE OMVATTEND ALISKIREN OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, EN AMLODIPINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/11/686/001-056 20110114
0503785/02Switzerland► SubscribeFORMER OWNER: SANKYO COMPANY LIMITED, JP
0503785/03Switzerland► SubscribeFORMER REPRESENTATIVE: BOHEST AG, CH
07C/043Belgium► SubscribePRODUCT NAME: AMLODIPINE ET VALSARTAN; NATL. REGISTRATION NO/DATE: EU/1/06/370/001 20070118; FIRST REGISTRATION: CH 57771 20061222
C0041Belgium► SubscribePRODUCT NAME: LEVOFLOXACINUM HEMIHYDRICUM; NAT. REGISTRATION NO/DATE: 354 IS 370 F3 19980624; FIRST REGISTRATION: GB 134020011 19970606
00528Netherlands► SubscribePRODUCT NAME: COMBINATIE VAN ALISKIREN OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, AMLODIPINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN EN HYDROCHLOORTHIAZIDE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; NATL. REGISTRATION NO/DATE: EU/1/11/730/001-060 20111122; FIRST REGISTRATION: CH 61678 01-05 20110705
2015000077Germany► SubscribePRODUCT NAME: EDOXABAN, DESSEN SALZ, DESSEN SOLVAT, ODER DESSEN N-OXID, INSBESONDERE EDOXABANTOSILAT; REGISTRATION NO/DATE: EU/1/15/993/001-028 20150619
315Luxembourg► SubscribePRODUCT NAME: COMBINAISON COMPRENANT ALISKIREN,OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLE,ET AMLODIPINE,OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLE
C/GB99/008United Kingdom► SubscribePRODUCT NAME: 2-N-BUTYL-4-SPIROCYCLOPENTANE-1-((2'-(TETRAZOL-5-YL)BIPHENYL-4-YL)METHYL)-2-IMIDAZOLIN-5-ONE)(GENERIC NAME IRBESARTAN) OPTIONALLY IN THE FORM OF ONE OF ITS SALTS AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/98/086/001 19981015; UK EU/1/98/086/002 19981015; UK EU/1/98/086/003 19981015; UK EU/1/98/086/004 19981015; UK EU/1/98/086/005 19981015; UK EU/1/98/086/006 19981015
0503785/01Switzerland► SubscribeFORMER OWNER: SANKYO COMPANY LIMITED, JP
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Mallinckrodt
Dow
Healthtrust
Covington
Accenture
Citi
Cerilliant
Teva
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot